BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 1826536)

  • 1. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)].
    Tanosaki R; Okamoto S; Takahashi S; Inoue T; Kikuno K; Aoki Y; Takada M; Irie S; Shimane M; Tojo A
    Rinsho Ketsueki; 1993 Aug; 34(8):946-51. PubMed ID: 8105115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
    Bettelheim P; Valent P; Andreeff M; Tafuri A; Haimi J; Gorischek C; Muhm M; Sillaber C; Haas O; Vieder L
    Blood; 1991 Feb; 77(4):700-11. PubMed ID: 1993213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
    Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
    Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
    Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
    Bernell P; Kimby E; Hast R
    Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of rhGM-CSF on Ara-C sensitivity of patients with acute myeloid leukemia in relapse: a flow cytometry study.
    Lacombe F; Puntous M; Dumain P; Cony-Makhoul P; Belloc F; Bernard P; Boisseau M; Reiffers J
    Leuk Res; 1996 Jun; 20(6):481-9. PubMed ID: 8709620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
    Cannistra SA; Groshek P; Griffin JD
    Leukemia; 1989 May; 3(5):328-34. PubMed ID: 2654494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z; Estey EH; Andreeff M; Talpaz M; Kurzrock R; Reading CL; Deisseroth AB; Gutterman JU
    Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
    te Boekhorst PA; Löwenberg B; Sonneveld P
    Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction.
    Lanza F; Rigolin GM; Castagnari B; Moretti S; Castoldi G
    Haematologica; 1997; 82(2):239-45. PubMed ID: 9175331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.
    Yang GS; Minden MD; McCulloch EA
    Leukemia; 1993 Jul; 7(7):1012-9. PubMed ID: 7686602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
    Wörmann B; Reuter C; Zühlsdorf M; Büchner T; Hiddemann W
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):39-43. PubMed ID: 7801145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.